Rx Cost-Effectiveness Research Is Government's Job, But Not FDA's, AMCP Says
This article was originally published in The Pink Sheet Daily
Executive Summary
AHRQ and NIH have role in carrying out post-approval drug research, but FDA's authority is limited to approving drugs based on safety and efficacy, Academy of Managed Care Pharmacy policy statement says.
You may also be interested in...
Comparative Research Should Start With Rx Drugs, AHRQ Says
AHRQ starts developing priority list of products for comparative research agenda with solicitation of comments in the Federal Register. An HHS steering committee will prioritize stakeholder proposals.
Comparative Research Should Start With Rx Drugs, AHRQ Says
AHRQ starts developing priority list of products for comparative research agenda with solicitation of comments in the Federal Register. An HHS steering committee will prioritize stakeholder proposals.
FDA To Adopt Cost-Effectiveness Role? Congress May Revisit Issue, Crawford Says
Medicare reform will link FDA more closely with CMS, which could necessitate FDA becoming more economically aware of approval decisions, Acting Commissioner Crawford says. FDAer envisions a relationship with CMS that is akin to a merger.